BioNTech SE

NASDAQ: BNTX
$130.30
+$2.65 (+2.1%)
Closing price September 27, 2022
Wednesday's additional top analyst upgrades and downgrades included Bath & Body Works, BioNTech, Caesars, Freeport McMoRan, Gap, Hasbro, and Synchrony Financial.
Here are previews of four interesting companies set to report quarterly results after the markets close on Tuesday and before they open on Wednesday.
Tuesday's top analyst upgrades and downgrades included BioNTech, ConocoPhillips, Harley-Davidson, Livent, Luminar Technologies, Meta Platforms, Moderna, Snap, Twitter, United Airlines, US Foods,...
Thursday afternoon's top analyst upgrades and downgrades included AT&T, BioNTech, Chewy, DocuSign, Ford, GM, Shopify, Toast, and more.
Wednesday afternoon's analyst upgrades and downgrades included BioNTech, ConocoPhillips, Casper Sleep, DoorDash, Palantir and Poshmark.
Here are three companies scheduled to report quarterly results before markets open on Tuesday.
Thursday afternoon's analyst upgrades and downgrades included Amazon, Bank of America, BioNTech, Chipotle, Disney and more.
COVID-19 vaccine co-developer BioNTech reports June quarter earnings before markets open Monday morning. So do two hot stocks in Cathie Wood's ETF portfolio.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Monday, including Acceleron Pharma, BioNTech, CyberArk Software, Five9 and Vertex Pharmaceuticals.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including BioNTech, Denali Therapeutics, Exelixis, Foot Locker and Hostess Brands.
After a quiet Friday afternoon, March quarter earnings hit the ground running again before markets open Monday. More than 1,500 earnings reports are expected next week.
Here are five stocks that reported earnings in the past week and all posted better-than-expected numbers and investors rewarded them with higher share prices.
Two interesting earnings reports are due early next week. One is recent entry in the electric vehicle market and the other is a co-developer of a COVID-19 vaccine.
BioNTech was in the spotlight on Tuesday after it received a sizable price target hike from one key analyst.
COVID-19 stocks were on the move on Wednesday after a few huge updates in regards to vaccine approval.